home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

How Do Inhibitors Activate Kinases?

  June, 4 2009 8:16
your information resource in human molecular genetics

Inhibitor binding leads to pre-activation of two kinases according to papers published online at Nature Chemical Biology and Nature Structural & Molecular Biology. The surprising finding may have important implications for drug discovery.

Kinases, which are a type of enzyme, are often 'primed' for full activity by the addition of small chemical groups called phosphates. Kinase inhibitors, used clinically to treat cancer, function by blocking kinase activity. As a result, it was unexpected when an inhibitor of the cancer-associated kinase Akt was found to cause the 'priming' phosphates to be added.

Using chemical tools to look closely at this phenomenon, Kevan Shokat and colleagues find that binding of the Akt inhibitor is directly responsible for this increased phosphorylation. Peter Parker and colleagues find a similar effect with the related kinase PKCε - inhibitor binding directly triggers priming phosphorylation.

Since, as discussed in an accompanying commentary by Stephen Frye and Gary Johnson, it may not be desirable to have drugs that increase the activity 'readiness' of the kinases they are designed to inhibit, these results have important implications for drug discovery.

Author contacts:

Kevan Shokat, (University of California, San Francisco, CA, USA)
E-mail: shokat@cmp.ucsf.edu

Peter Parker (Cancer Research UK, London, UK)
E-mail: peter.parker@cancer.org.uk

Stephen Frye (University of North Carolina, Chapel Hill, NC, USA)
E-mail: sfrye@email.unc.edu

Abstracts available online:
Abstract 1.
Abstract 2.
Abstract 3.

(C) Nature Chemical Biology press release.

(C) Nature Structural & Molecular Biology press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.